Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

Inclusion Criteria:

• Diagnosed with gout

Exclusion Criteria:

• Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)